Effective Salvage Therapy for HIV-1 Infection – An Unmet Challenge

Palella F.J. , Delaney K.M. , Moorman A.C. , Loveless M.O. , Fuhrer J. , Satten G.A. , Aschman D.J. , & Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient study investigators. New England Journal of Medicine 1998; 338: 853–860.

Gulick R.M. Responses to specific salvage therapy regimens. 2nd International Workshop on Salvage Therapy for HIV Infection, 19–21 May 1999, Toronto, Canada. Abstract 012.

Gulick R.M. , Katzenstein D. , Hu J. , Fiscus S. , Fletcher C.V. , Haubrich R. , Cheng H. , Lagakos S. , Acosta E. , Swanstrom R. , Mills C. , Snyder S. , Fischl M. , & Pettinelli C for the ACTG 359 Team. Salvage therapy with saquinavir soft gel capsules in combination with ritonavir or nelfinavir and delavirdine, adefovir dipivoxil. 2nd International Workshop on Salvage Therapy for HIV Infection, 19–21 May 1999, Toronto, Canada. Abstract 020.

Miller F. , Staszewski S. , Sabin C. , Rottmann C. , Cozzi-Lepri A. , Hill A. , Phillips A.N. CD4 lymphocyte count as a predictor of the duration of HAART-induced suppression of HIV-1 virus load. 2nd International Workshop on Salvage Therapy for HIV Infection, 19–21 May 1999, Toronto, Canada. Abstract 010.

Miller V. , Rottmann C. , Hertogs K. , Larder B.A. , Phillips AN Cozzi-Lepri A. , Sturmer M. , Gute P. , & Staszewski S. Mega-HAART, resistance and drug holidays. 2nd International Workshop on Salvage Therapy for HIV Infection, 19–21 May 1999, Toronto, Canada. Abstract 030.

Youle M. , Mocroft A. , Johnson M. , Tyrer M. , Madge S. , Dykhoff A. , & Drinkwater A. Surrogate marker responses to multidrug combinations comprising hydroxyurea, efavirenz, double protease inhibitors (PI) and nucleoside analogues in PI failures. 2nd International Workshop on Salvage Therapy for HIV Infection, 19–21 May 1999, Toronto, Canada. Abstract 018.

Montaner J.S.G. , Harrigan P.R. , Jahnke N.A. , Hogg R.S. , Yip B. , Harris M. , Montessori V. , & O'Shaughnessy M V. Multidrug rescue therapy for HIV-infected individuals with prior virological failure to multiple regimens: results from an initial cohort. 2nd International Workshop on Salvage Therapy for HIV Infection, 19–21 May 1999, Toronto, Canada. Abstract 015.

Montaner J.S.G. , Harrigan P.R. , Jahnke N.A. , Hogg R.S. , Yip B. , Harris M. , Montessori V. , & O'Shaughnessy M V. Multidrug rescue therapy for HIV-infected individuals with prior virological failure to multiple regimens: results from a second cohort. 2nd International Workshop on Salvage Therapy for HIV Infection, 19–21 May 1999, Toronto, Canada. Abstract 016.

Baxter J.D. , Mayers D.L. , Wentworth D.N. , Neaton J.C. , Merigan T.C. and the CPCRA 046 Study Team. A pilot study of the short-term effects of antiretroviral management based on plasma Genotypic Antiretroviral Resistance Testing (GART) in patients failing antiretroviral therapy. 6th Conference on Retroviruses and Opportunistic Infections, 31 January–4 February 1999, Chicago, Ill., USA. Abstract LB8.

Durant J. , Clevenbergh P. , Halfon P. Can genotype determination be useful for individualized adaptation of antiretroviral therapy: the VIRADAPT French study. AIDS 1998; 12(Suppl. 4):S16.

Murphy R.L. New agents and regimens for salvage therapy. 2nd International Workshop on Salvage Therapy for HIV Infection, 19–21 May 1999, Toronto, Canada. Abstract 001.

Miller M.D. , Coleman R.L. , Wiznia A. , Winslow D.L. , & Coakley D.F. Durable HIV RNA reductions seen in pediatric patients with pre-existing nucleoside resistance mutations treated with adefovir dipivoxil, nelfinavir and other nucleoside inhibitors. 2nd International Workshop on Salvage Therapy for HIV Infection, 19–21 May 1999, Toronto, Canada. Abstract 017.